<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

SK-OV-3

Description

SK-OV-3 (Ovarian Cancer CDX Model) 

The SK-OV-3 ovarian cancer line was derived from an ovarian adenocarcinoma. It is HER2-positive, making it relevant for targeted therapy studies. SK-OV-3 is widely applied in ovarian cancer drug discovery. Its reproducibility makes it a standard preclinical model. 

Key Features: 

  • Derived from ovarian adenocarcinoma. 
  • HER2-positive ovarian cancer line. 
  • Aggressive xenograft growth. 
  • Epithelial carcinoma morphology. 

Applications: 
SK-OV-3 supports targeted therapy research for ovarian cancer. It is used in biomarker validation and drug resistance studies. Researchers apply it in preclinical screening programs. Its HER2 positivity provides translational value for therapy development.

Details
Tumor Type
Ovarian, Fallopian Tube
Tumor Subtype
Serous carcinoma of the ovary
Organism
Human
Mouse Sex
Female
Mouse Strain
NOG
Mutated Genes
ARID1A
Mutation: p.Q586Ter
Effect: Stop-Gain
ATM
Effect: Splice Acceptor Variant
Impact: Likely Pathogenic & Uncertain Significance
PIK3CA
Mutation: p.H1047R
Effect: Missense Variant
Impact: Pathogenic / Likely Pathogenic & Likely Pathogenic & Pathogenic
TP53
Mutation: p.S90PfsTer33
Effect: Frameshift Variant
Impact: Likely Pathogenic & Pathogenic
Lumin Data
Proteomics RNASeq WES
Expression Data
Growth Curve
View on Lumin